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The biosimilars sector continues to attract huge interest and controversy. Biosimilars are new bio-
pharmaceuticals that are “similar” but not identical to the innovator product. Characteristics of bio-
pharmaceuticals are closely related to the manufacturing process, which implies that the products
cannot be exactly duplicated. Minuscule differences in the product’s structure and manufacturing
process can result in different clinical outcome. This raises concerns over the safety, efﬁcacy and even
pharmacovigilance of biosimilars. Thus, biosimilars are unique e they are not a true chemical generic
and are regulated via a distinct regulatory framework. This report discusses the features of Malaysian
regulatory oversight of biosimilars and experience acquired in the evaluation of some products from
various countries. Ensuring regulatory position adequately reﬂects scientiﬁc advancement, expertise/
resources is key. The regulatory situation is an evolving process. Various guidance documents are being
prepared with the aim of developing a uniform global framework towards assuring the dual goal of lower
costs and patient safety while expediting the availability of important biosimilar products.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Biopharmaceuticals are medicinal products consisting of (glyco)
proteins and/or ‘nucleic acids’, developed by means of biotech-
nology processes such as recombinant DNA, controlled gene
expression and other novel production methods. Biotherapeutics
were introduced in the market in the early 1980s, setting new
milestones in modern pharmaceutical therapy resulting in poten-
tially life-saving medical treatments for some of the most serious
diseases and offering improvements in quality of life of patients.
Biopharmaceuticals are produced from living cells/systems.
They are relatively large and complex molecules. They are almost
impossible to replicate and minuscule differences in product’s
structure and manufacturing process can result in different clinical
outcome. Unlike a chemical generic, a biosimilar product is one that
is ‘not identical’ but highly similar in physico-chemical and
biological characteristics to an innovator product. The inherent
differences between any two biopharmaceuticals have the poten-
tial to produce dissimilarities in pharmacological properties, clin-
ical efﬁcacy, safety and immunogenicity. These raise concerns over
the safety/efﬁcacy and even pharmacovigilance of biosimilars.
Clearly, the generic approach is scientiﬁcally not appropriate to
biosimilars and additional non-clinical and clinical data are usuallyll rights reserved. The World Healthrequired. Hence, a biosimilar approval pathway was developed in
which comparability exercise(s) in terms of quality, efﬁcacy and
safety is required. This further avoids an inordinate impact of
development costs in new biopharmaceuticals.
The regulatory situation is an evolving process. This document is
intended to provide information on the guidance available in
Malaysia for the development and requirements for biosimilars.
The guidelines are intended to serve as a live document that will
evolve with further progress of scientiﬁc knowledge, advances in
analytics and more experience.
2. Legislation
The legislative basis for the registration and marketing authori-
zation of pharmaceuticals including biopharmaceuticals inMalaysia
is the Control Of Drugs And Cosmetics Regulations (CDCR 1984)
promulgated under the Sale Of Drugs Act 1952 (ACT 368). Biosimilar
products are considered new biological medicinal products and are
therefore regulated under the same legislation. The National
Regulatory Authority (NRA) for medicinal products is the National
Pharmaceutical Control Bureau, Ministry Of Health, Malaysia [1].
Malaysia’s guidance document and guidelines for registration of
biosimilars was ﬁnalized in August 2008. The information in the
guidance was adopted from the European Medicines Agency (EMA)
comprehensive scientiﬁc biosimilar guidelines (including the
product speciﬁc and other guidelines relevant to biosimilars), with
some adaptations for Malaysian applications [2].Organization has granted the Publisher permission for the reproduction of this article.
A. Abas / Biologicals 39 (2011) 339e342340All relevant International Conference of Harmonization (ICH)
Guidelines on biological products containing biotechnology-
derived proteins as an active substance, are used as the basis for
deﬁning the registration requirements. The document also includes
a provision to align or harmonize the regulatory oversight of bio-
similars with the global regulatory guideline including the World
Health Organization (WHO) Guidelines On Evaluation Of Similar
Biotherapeutic Products (SBPs) [3].
3. Scope and guiding principles
A biosimilar is deﬁned as a new biological medicinal product
developed to be similar in terms of quality, safety and efﬁcacy to an
already registered, well-established medicinal product/innovator
product.
The aim of the biosimilar approach is to demonstrate close
similarity of the biosimilar product in terms of quality, safety and
efﬁcacy to one chosen reference medicinal product. A high degree
of similarity between the biosimilar and the reference product is
the basis for a reduced non-clinical and clinical package [3,4].
The demonstration of similarity depends upon detailed and
comprehensive product characterization, therefore, information
requirements outlined within the guideline apply to well-estab-
lished and well-characterized biopharmaceutical product such as
recombinantDNA-derived therapeutic proteins. Biosimilar approach
is not applicable to more complex biopharmaceuticals such as blood
products, vaccines and other immunologicals.
4. Policy statements
The following policy statements outline the fundamental
concepts and principles constituting the basis of the regulatory
framework for biosimilars:
1. Biosimilars are not ‘generic biologics’ or ‘biogenerics’. Conven-
tional generics of chemical drugs are approved if pharmaceu-
tical equivalence (i.e identical active substances) and
bioequivalence (i.e comparable pharmacokinetics) compared
with the innovator drug have been established. Thus, clinical
efﬁcacy and safety studies are not needed. This generic para-
digm cannot be applied to therapeutic proteins.
2. Approval of a product through the biosimilar pathway is not an
indication that the biosimilar may be automatically substituted
with its reference product. The decision for interchangeability
with the reference product shall be based on science and
clinical data.
3. Eligibility for a biosimilar pathway hinges on the ability to
demonstrate similarity to a reference product. Product
employing clearly different approaches to manufacture than
the reference product (for example use of transgenic organisms
versus cell culture) will not be eligible for the regulatory
pathway for biosimilars.
5. The biosimilar manufacturer must conduct a direct and
extensive comparability exercise(s) between its product and
the reference product, in order to demonstrate that the two
products have a similar proﬁle in terms of quality, safety and
efﬁcacy. Only one reference product is allowed throughout this
exercise. The rationale for the choice of reference product
should be provided by the manufacturer to the NRA.
6. Non-clinical and clinical requirements outlined for biosimilar
submission in the guidance document are applicable to bio-
similars that have demonstrated similarity to the reference
product, based on results of the comparability exercise(s) from
chemistry, manufacturing and control (CMC) perspectives.
When the similarity of a biosimilar cannot be adequatelyestablished, the submission of such a product should be as
a ‘stand-alone’ biotechnological product.
7. It should be recognized that there may be subtle differences
between biosimilars fromdifferentmanufacturers or compared
with reference products, which may not be fully apparent until
greater experience in their use has been established. Therefore,
in order to support pharmacovigilance monitoring, the speciﬁc
biosimilar given to the patient should be clearly identiﬁed by
explicit use of brand name, for example.
8. It was acknowledged that although International Non-
proprietary Names (INNs) served as a useful tool in world-
wide pharmacovigilance, for biologicals they could not be
relied upon as the only means of product identiﬁcation, nor as
an indicator of interchangeability or substitution.
9. The prescribing information for a biosimilar should be as
similar as possible to that of the reference product except for
product-speciﬁc aspects such as different excipient(s), clinical
studies performed, route of administration etc. This is partic-
ularly important and may affect the clinical behavior. There-
fore, automatic substitution and active substance-based
prescription cannot apply to biosimilars. Such an approach
ensures that the treating physicians can make informed deci-
sions about treatments in the interest of patient safety.5. Malaysian biosimilar guidelines versus WHO similar
biotherapeutic products guidelines
Generally the two guidelines are complementary as they are
based on similar principles. However, it is noted that the WHO
guidelines emphasize on the evaluation of SBPs, thus is very useful.
However, the following are speciﬁc concepts in the Malaysian
perspective:
5.1. Reference product
The reference product is deﬁned as a medicinal product
already approved/registered in Malaysia on the basis of
a complete dossier (quality, safety and efﬁcacy), chosen as
a reference product by the biosimilar manufacturer. The same
reference product should be used throughout the development
program for quality, safety and efﬁcacy studies and the compa-
rability exercise(s). Alternatively, a medicinal product registered
in the reference countries [Australia, Canada, EU (via centralized
procedure), United Kingdom, France, Japan, Sweden, Switzerland,
and the USA] is considered acceptable. The product should have
suitable duration of registration (5 years) and volume of mar-
keted use.
5.2. Interchangeability/switching and substitution
The WHO leaves the issue to the policy or practice of individual
country. When biosimilars are approved, they will be considered
comparable to the reference product, but this does not necessary
imply therapeutic equivalence. The inherent differences between
any two biopharmaceuticals have the potential to produce
dissimilarities in pharmacological properties, clinical efﬁcacy,
safety and immunogenicity. Switching from one biopharmaceutical
to any other can be viewed as a change in clinical management and
require appropriate monitoring. The pharmacovigilance program
must be rigorous to build an accurate database establishing the
clinical use of each product and may include patient registries and
retrospective or prospective observational studies. Therefore, for
a variety of reasons, automatic substitution is not allowed for bio-
similar product [4e7].
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For a biosimilar manufacturer from a country that is not within
the Pharmaceutical Inspection Convention/Scheme (PIC/S) member
countries or from the eight Malaysian reference countries, a GMP
on-site audit of the manufacturing facilities is mandatory.
5.4. Efﬁcacy studies
To demonstrate the similarity in the efﬁcacy proﬁle of the bio-
similar product and the reference product, an equivalence trial is
advocated. However, the WHO Guidelines on SBPs provide an
overview of the advantages and disadvantages of non-inferiority
trials, with a caveat there is no experience with the non-
inferiority trial to date.
6. Malaysian experience in registration of a biosimilar
product and others
There is one biosimilar product approved recently (October
2010) in Malaysia. The product contains Somatropin, brand name is
SciTropin A, manufactured by Sandoz GmbH, Austria and was
secondary packaged in Singapore. It is also known as Omnitrope
in many other countries.
SciTropin A, was classiﬁed as a biosimilar as it complies with
the requirements of a biosimilar. The approval process for SciTropin
A included a number of comparability studies to the reference
product Genotropin including quality, pharmacokinetic and
pharmacodynamic, clinical efﬁcacy, safety and immunogenicity
studies.
A key safety parameter of biotherapeutic products is immuno-
genicity i.e the ability of a substance to trigger an immune response
in the patient. Clinical trials and a robust post marketing pharma-
covigilance are essential to guarantee product safety and efﬁcacy
over time. Such pharmacovigilance plans need to be tailored to
each product and a Risk Management Plan (RMP) approved prior to
product approval [7,8]. The marketing authorization holders (MAH)
of biosimilars should make sure that they have an appropriate
system of pharmacovigilance in place to assure responsibility of
their products on the market and to ensure that appropriate action
can be taken, if necessary. The conclusion of biosimilarity for Sci-
Tropin A, was provided by the totality of evidence in quality, safety
and efﬁcacy. It was given registration subject to post-approval
commitments to provide follow-up safety assessments.
Our experience in evaluating several “intended copies” or “bio-
copies” of biopharmaceuticals, although claimed to be biosimilar
products (such as Interferon alpha-2a, Filgrastim and Erythropoi-
etin) from countries considered to have less stringent regulatory
standards than the EU and the USA highlighted many inadequacies
and shortfalls of the dossiers. Typical shortfalls identiﬁed which
resulted in non-approval of the products are listed below:
 There was a paucity of data in all aspects of product develop-
ment, manufacture and control of drug substance and drug
product.
 The reference product chosen was not justiﬁed and isolation
process was not described and justiﬁed.
 No or minimal comparability exercise(s) was carried out.
Speciﬁcations chosen were not clear, hence quality
questionable.
 Description of the puriﬁcation was limited and investigation of
impurities was insufﬁcient.
 Batch-to-batch consistency was not demonstrated.
 Validation of infectious agents, TSE assessment was not
provided. Quality control: inadequate testing and non-orthogonal
approach. Poor analytical characterization and validation.
 Although the analytical tools used for assessment of quality
were those described in the pharmacopeial monographs, only
limited data showing the physico-chemical and biochemical
characteristics of the protein were provided. Consequently, the
comparability data provided was insufﬁcient to establish
similarity of the reference and the copy product at the quality
level.
 Stability studies data were limited and stability proﬁles could
not be established.
 Minimalistic non-clinical studies, non-sensitive species were
used.
 Inadequate clinical datawith poor study designs, small number
of subjects and short duration of studies, therefore
inconclusive.
 Safety: lack of risk management strategies and no pharmaco-
vigilance data.
 Immunogenicity of the product was not investigated and was
not properly evaluated.
 Prescribing information and labeling was very minimal.
Based on the above, sufﬁcient information showing the bio-
similarity of the copy product to the reference product was clearly
lacking. These copy products have been licensed following the
national regulations on the basis of a reduced data package and
presumably not advocating stringent demands on demonstrating
similarity via comparability exercise(s) [9,10]. Nevertheless, these
served as a good learning platform and provided a discriminating
insight of the dossier and a challenge to our evaluation skills.
In this respect, since the scientiﬁc justiﬁcation for the various
approval pathways is not clear in all cases, theWHO has recognized
a need for deﬁning regulatory expectations for these products to
promote global consensus on the regulation of biosimilars and thus
enhance the availability of safe and effective biosimilar products
worldwide.
7. Conclusion
Why biosimilars e and why now? As patents on earlier bio-
pharmaceuticals have either expired or about to expire, this creates
a clear market opportunity to non-innovator versions of these
products called biosimilars. Secondly, the biopharmaceuticals are
very expensive and thus, are unaffordable to many patients and
cause concerns to ever increasing healthcare costs globally.
Understandably, there is a compelling need to make biosimilar
more widely available and cheaper. In light of existing scientiﬁc
evidence, the regulatory paradigm for biosimilars will have to go
beyond mere cost-effectiveness to protect public health. Therefore,
the other critical elements in the value equation namely e quality
and patient safety emust be given equal importance. Lower cost at
the expense of patient safety is no bargain.
The biotechnology sector is at an exciting stage in its life cycle. It
can no longer be considered an emerging industry, but neither is it
yet a mature industry. Likewise, the rapidly expanding ﬁeld of
biosimilars calls for awareness, alertness and education of all
stakeholders. Given these complexities and many other emerging
uncertainties, it is important for all stakeholders to work together
to evolve a viable and pragmatic regulatory oversight framework
and clinical utilization of biosimilars.
Regulation of biosimilars will be a major challenge for NRAs for
years to come. Ensuring regulatory position adequately reﬂects that
scientiﬁc advancement, expertise, resources and capacity building
are essential. Accrued experience will then allow regulatory author-
ities to optimally match guidelines to the genuine risks and beneﬁts
A. Abas / Biologicals 39 (2011) 339e342342associated with biosimilars. Clearly, this area of rapidly evolving
regulatory science would beneﬁt from better cooperation, informa-
tion exchange and collaboration from different regulators interna-
tionally. Undoubtedly, squaring the circle will take some doing.
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